These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 3568269)

  • 1. Expressions of resistance and cross-resistance in teniposide-resistant L1210 cells.
    Roberts D; Lee T; Parganas E; Wiggins L; Yalowich J; Ashmun R
    Cancer Chemother Pharmacol; 1987; 19(2):123-30. PubMed ID: 3568269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced formation of lesions in the DNA of a multidrug-resistant L1210 subline selected for teniposide resistance.
    Roberts DW; Foglesong PD; Parganas E; Wiggins L
    Cancer Chemother Pharmacol; 1989; 23(3):161-8. PubMed ID: 2538249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flux of teniposide (VM-26) across the plasma membrane of teniposide-resistant sublines of L1210 cells.
    Lee T; Roberts D
    Cancer Res; 1984 Jul; 44(7):2986-90. PubMed ID: 6722822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection and characterization of L1210 sublines resistant to teniposide (VM-26).
    Lee T; Roberts D
    Cancer Res; 1984 Jul; 44(7):2981-5. PubMed ID: 6722821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of sorcin with drug resistance in L1210 cells.
    Roberts D; Meyers MB; Biedler JL; Wiggins LG
    Cancer Chemother Pharmacol; 1989; 23(1):19-25. PubMed ID: 2909286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effectiveness of a range of novel drug-resistance modulators, relative to verapamil, in influencing vinblastine or teniposide cytotoxicity in human lymphoblastoid CCRF-CEM sublines expressing classic or atypical multidrug resistance.
    Hill BT; Hosking LK
    Cancer Chemother Pharmacol; 1994; 33(4):317-24. PubMed ID: 8281626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26).
    Danks MK; Yalowich JC; Beck WT
    Cancer Res; 1987 Mar; 47(5):1297-301. PubMed ID: 3469013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
    Wolverton JS; Danks MK; Schmidt CA; Beck WT
    Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.
    Chen M; Beck WT
    Cancer Res; 1993 Dec; 53(24):5946-53. PubMed ID: 8261408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro comparison of podophyllotoxin analogues; etoposide, teniposide and NK 611 using human lung cancer cell lines].
    Takigawa N; Ohnoshi T; Ueoka H; Kiura K; Moritaka T; Tabata M; Segawa Y; Shibayama T; Gemba K; Matsumura T
    Gan To Kagaku Ryoho; 1993 Mar; 20(4):473-7. PubMed ID: 8383949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA.
    Fernandes DJ; Danks MK; Beck WT
    Biochemistry; 1990 May; 29(17):4235-41. PubMed ID: 2163274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein-linked DNA strand breaks produced by etoposide and teniposide in mouse L1210 and human VA-13 and HT-29 cell lines: relationship to cytotoxicity.
    Kerrigan D; Pommier Y; Kohn KW
    NCI Monogr; 1987; (4):117-21. PubMed ID: 3041238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiation of etoposide-induced DNA damage by calcium antagonists in L1210 cells in vitro.
    Yalowich JC; Ross WE
    Cancer Res; 1984 Aug; 44(8):3360-5. PubMed ID: 6744270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic, biochemical, and cross-resistance studies with mutants of Chinese hamster ovary cells resistant to the anticancer drugs, VM-26 and VP16-213.
    Gupta RS
    Cancer Res; 1983 Apr; 43(4):1568-74. PubMed ID: 6831403
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of 1-beta-D-arabinofuranosylcytosine transport and net accumulation by teniposide and etoposide in Ehrlich ascites cells and human leukemic blasts.
    White JC; Hines LH; Rathmell JP
    Cancer Res; 1985 Jul; 45(7):3070-5. PubMed ID: 4005845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased ATP requirement for activity of and complex formation by DNA topoisomerase II from human leukemic CCRF-CEM cells selected for resistance to teniposide.
    Danks MK; Schmidt CA; Deneka DA; Beck WT
    Cancer Commun; 1989; 1(2):101-9. PubMed ID: 2561733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
    Rappa G; Lorico A; Sartorelli AC
    Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines.
    Matsuo K; Kohno K; Takano H; Sato S; Kiue A; Kuwano M
    Cancer Res; 1990 Sep; 50(18):5819-24. PubMed ID: 2168282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
    Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM
    Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calmodulin inhibitor trifluoperazine in combination with doxorubicin induces the selection of tumour cells with the multidrug resistant phenotype.
    Kamath N; Grabowski D; Ford J; Ganapathi R
    Br J Cancer; 1993 Jun; 67(6):1203-8. PubMed ID: 8099806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.